Showing results (521-530 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|April 29, 2021
Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trialAdriana Weinberg, Petronella Muresan, Lauren Laimon, et al.
The Lancet. HIV|June 7, 2020
HIV outbreaks among people who inject drugs in Europe, North America, and IsraelDon C Des Jarlais, Vana Sypsa, Jonathan Feelemyer, et al.
The Lancet. HIV|July 14, 2025
Lessons for long-acting lenacapavir: catalysing equitable PrEP access in low-income and middle-income countriesSharonann Lynch, Rachel M Cohen, Matthew Kavanagh, et al.
The Lancet. HIV|June 21, 2025
Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisGert van Zyl, Mateo Prochazka, Heather-Marie Ann Schmidt, et al.
The Lancet. HIV|June 22, 2025
Predictors of treatment-emergent resistance to dolutegravirSuzanne M McCluskey, Monica Gandhi
The Lancet. HIV|November 30, 2025
Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysisShona Dalal, Karin Sundström, Ronaldo Silva, et al.
The Lancet. HIV|February 17, 2025
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohortMichael Pickles, Simon Gregson, Louisa Moorhouse, et al.
The Lancet. HIV|January 20, 2025
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVESteven K Grinspoon, Markella V Zanni, Virginia A Triant, et al.
The Lancet. HIV|January 8, 2025
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohortVita W Jongen, Ferdinand W N M Wit, Anders Boyd, et al.
The Lancet. HIV|January 18, 2025
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trialEzequiel Cordova, Jeniffer Hernandez Rendon, Veronica Mingrone, et al.
Pageof 79